DDInter1321 DDInter1676
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ocrelizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib